An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
AtriCure to Participate in Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), announced its participation in major investor conferences. Management will present at the Stifel 2022 Healthcare Conference on November 16, 2022, at 11:30 a.m. ET, with a live audio webcast available on their website. Additionally, they will host investor meetings at the Canaccord Genuity Medtech Forum on November 17, 2022. AtriCure provides innovative technologies including the Isolator® Synergy™ Ablation System and AtriClip® for Afib treatment, affecting over 37 million people worldwide.
Positive
None.
Negative
None.
MASON, Ohio--(BUSINESS WIRE)--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in upcoming investor conferences.
AtriCure’s management is scheduled to present at the Stifel 2022 Healthcare Conference on Wednesday, November 16, 2022, at 11:30 a.m. Eastern Time. Interested parties may access a live audio webcast of the presentation by visiting the “Investors” section of the company’s website at https://ir.atricure.com.
AtriCure’s management is also scheduled to host investor meetings at the Canaccord Genuity Medtech, Diagnostics and Digital Health & Services Forum on Thursday, November 17, 2022.
About AtriCure
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.
When is AtriCure presenting at the Stifel 2022 Healthcare Conference?
AtriCure will present at the Stifel 2022 Healthcare Conference on November 16, 2022, at 11:30 a.m. Eastern Time.
How can I access AtriCure's presentation during the conference?
The presentation can be accessed via a live audio webcast on AtriCure's website under the 'Investors' section.
What other investor meetings is AtriCure participating in?
AtriCure will also host investor meetings at the Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum on November 17, 2022.
What technologies does AtriCure provide for Afib treatment?
AtriCure's technologies include the Isolator® Synergy™ Ablation System and AtriClip® Left Atrial Appendage Exclusion System, designed for the treatment of Afib.
How many people are affected by atrial fibrillation globally?
Atrial fibrillation affects over 37 million people worldwide.
